[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 31 of about 31
1. Savvides PP: The role of chemotherapy in the management of patients with head and neck cancer. Semin Plast Surg; 2010 May;24(2):137-47

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of chemotherapy in the management of patients with head and neck cancer.
  • Recent advances in the management of patients with head and neck cancer point to an expanding role of chemotherapy, resulting in an increased involvement of the medical oncologist in the multidisciplinary care of these patients.
  • This review focuses on patients with squamous cell carcinoma of the oral cavity, pharynx, and larynx.
  • Information on human papilloma virus-associated squamous cell cancer of the head and neck is presented, and implications in the clinical management of this subgroup of patients based on the epidemiologic and pathologic characteristics are discussed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22550434.001).
  • [ISSN] 1535-2188
  • [Journal-full-title] Seminars in plastic surgery
  • [ISO-abbreviation] Semin Plast Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3324245
  • [Keywords] NOTNLM ; Cancer of the head and neck / chemotherapy / squamous cell carcinoma
  •  go-up   go-down


2. Shehab N, Sweet BV, Hogikyan ND: Cidofovir for the treatment of recurrent respiratory papillomatosis: a review of the literature. Pharmacotherapy; 2005 Jul;25(7):977-89
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cidofovir for the treatment of recurrent respiratory papillomatosis: a review of the literature.
  • Recurrent respiratory papillomatosis (RRP) is a rare but potentially severe disease caused by papillomavirus, most often types 6 and 11.
  • The disease, which occurs in both juvenile and adult forms, is characterized by benign epithelial tumors of the airway that most frequently affect the larynx but can also spread along the entire aerodigestive tract.
  • Recurrent respiratory papillomatosis is the most common benign neoplasm of the larynx in children and the second most frequent cause of childhood hoarseness.
  • Standard treatment, which is palliative only, consists of surgical excision of papillomata to maintain airway patency and improve voice quality.
  • To date, incorporation of adjuvant treatments has not been reliably beneficial in altering the disease course.
  • To evaluate the data available on the safety and efficacy of cidofovir for the treatment of RRP, we conducted a MEDLINE search for all case reports or series from January 1966-August 2004 describing cidofovir therapy in either adults or children with RRP.
  • Further studies are necessary to determine the most appropriate dose, frequency, and duration of therapy, and to fully characterize the safety profile profile of cidofovir when given intralesionally.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cytosine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Organophosphonates / therapeutic use. Papilloma / drug therapy. Respiratory Tract Neoplasms / drug therapy
  • [MeSH-minor] Adult. Child. Clinical Trials as Topic. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Injections, Intralesional. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / surgery. Male


3. Major T, Sziklai I, Czeglédy J, Gáll T, Gergely L, Szarka K: Follow-up of HPV DNA copy number in cidofovir therapy of recurrent respiratory papillomatosis. Anticancer Res; 2008 Jul-Aug;28(4B):2169-74
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follow-up of HPV DNA copy number in cidofovir therapy of recurrent respiratory papillomatosis.
  • BACKGROUND: Cidofovir is a cytosine nucleoside analogue antiviral drug given as an adjuvant therapy in recurrent respiratory papillomatosis (RRP).
  • MATERIALS AND METHODS: Intralesional cidofovir therapy was given to a 14-year-old male patient.
  • The papilloma severity score (PSS) of Derkay et al. was used for follow-up.
  • Serial fresh-frozen biopsies were taken from the lesions in the larynx and soft palate prior to therapy and during its course.
  • After human papillomavirus (HPV) typing and the determination of the genomic physical state, the HPV DNA copy number was estimated with real-time PCR.
  • RESULTS: All the papillomas harboured HPV 11 DNA in episomal form.
  • Prior to therapy, the HPV copy number fluctuated with time.
  • In the initial treatment period with 2-week-intervals both the viral load and the PSS decreased and a transient complete remission was observed.
  • CONCLUSION: The initial treatment period was successful, as the viral load decreased, and long-term effects of cidofovir might account for the controlled disease as the injection intervals were prolonged.
  • [MeSH-major] Cytosine / analogs & derivatives. DNA, Viral / genetics. Human papillomavirus 11 / genetics. Laryngeal Neoplasms / virology. Organophosphonates / therapeutic use. Papilloma / virology. Papillomavirus Infections / virology
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Antiviral Agents / therapeutic use. Gene Dosage. Humans. Male. Mouth Neoplasms / drug therapy. Mouth Neoplasms / virology. Palate, Soft / pathology. Viral Load

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18751391.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / DNA, Viral; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


Advertisement
4. Broekema FI, Dikkers FG: Side-effects of cidofovir in the treatment of recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol; 2008 Aug;265(8):871-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Side-effects of cidofovir in the treatment of recurrent respiratory papillomatosis.
  • Recurrent respiratory papillomatosis (RRP) is a chronic and difficult to treat disease of the larynx.
  • In these articles a total of 188 patients with RRP were described who underwent therapy with intralesional cidofovir.
  • Five of these patients have developed dysplasia of the larynx during the treatment with cidofovir.
  • Based on this review, it can be concluded that the use of intralesional cidofovir does not increase the risk of laryngeal dysplasia.
  • Apart from the articles that describe the intralesional administration of cidofovir, some articles have been published in which the use of intravenous cidofovir is described as a therapy for RRP.
  • Based on the outcomes of this review, recommendations are given for a safe use of cidofovir for treatment of recurrent respiratory papillomatosis in the future.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Cytosine / analogs & derivatives. Laryngeal Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Organophosphonates / adverse effects. Papilloma / drug therapy

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. CIDOFOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Antiviral Res. 1996 Mar;29(2-3):153-61 [8739595.001]
  • [Cites] Pediatr Clin North Am. 1996 Dec;43(6):1385-401 [8973518.001]
  • [Cites] J Med Virol. 1998 Mar;54(3):219-25 [9515772.001]
  • [Cites] Laryngoscope. 1998 May;108(5):735-40 [9591556.001]
  • [Cites] Clin Pharmacokinet. 1999 Feb;36(2):127-43 [10092959.001]
  • [Cites] Am J Surg Pathol. 1991 Sep;15(9):891-8 [1659237.001]
  • [Cites] Folia Biol (Praha). 1993;39(3):150-61 [8157136.001]
  • [Cites] J Laryngol Otol. 1998 Nov;112(11):1101-4 [10197157.001]
  • [Cites] Otolaryngol Head Neck Surg. 1999 May;120(5):698-705 [10229596.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1999 Oct;125(10):1143-8 [10522508.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Nov;130(11):1319-23 [15545589.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2004 Nov;113(11):859-62 [15562893.001]
  • [Cites] J Voice. 2004 Dec;18(4):551-6 [15567056.001]
  • [Cites] J Med Virol. 2005 Feb;75(2):332-5 [15602729.001]
  • [Cites] Acta Otorrinolaringol Esp. 2005 Jan;56(1):22-4 [15747720.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2005 Nov;69(11):1465-7 [16174538.001]
  • [Cites] Otolaryngol Head Neck Surg. 2005 Nov;133(5):666-71 [16274789.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2005 Nov;114(11):836-9 [16358603.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2006 Mar;115(3):175-81 [16572605.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1995 Oct;104(10 Pt 1):758-62 [7574251.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2006 May;263(5):440-3 [16328406.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 Jul;135(1):22-7 [16815177.001]
  • [Cites] J Laryngol Otol. 2006 Jul;120(7):561-5 [16834805.001]
  • [Cites] Paediatr Respir Rev. 2006;7 Suppl 1:S330 [17036412.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2006 Sep;115(9):667-72 [17044537.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2006 Nov;70(11):1911-7 [16919339.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2007 Jan;264(1):63-70 [17058091.001]
  • [Cites] Ear Nose Throat J. 2000 Apr;79(4):236-8, 240 [10786384.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2000 Oct;126(10):1239-43 [11031411.001]
  • [Cites] Chest. 2000 Oct;118(4):1210-4 [11035700.001]
  • [Cites] Expert Opin Investig Drugs. 2000 Feb;9(2):207-20 [11060672.001]
  • [Cites] Clin Infect Dis. 2001 Feb 1;32(3):E62-4 [11170974.001]
  • [Cites] Eur Respir J. 2001 Apr;17(4):830-1 [11401080.001]
  • [Cites] Otolaryngol Head Neck Surg. 2002 Jun;126(6):642-8 [12087331.001]
  • [Cites] Laryngoscope. 2002 Apr;112(4):696-9 [12150526.001]
  • [Cites] J Otolaryngol. 2002 Dec;31(6):333-5 [12593542.001]
  • [Cites] Rev Laryngol Otol Rhinol (Bord). 2002;123(5):315-20 [12741293.001]
  • [Cites] Otolaryngol Head Neck Surg. 2003 Jun;128(6):788-94 [12825028.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Aug;129(8):841-6 [12925342.001]
  • [Cites] Laryngoscope. 2003 Sep;113(9):1583-7 [12972938.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Oct;129(10):1081-5 [14568791.001]
  • [Cites] Laryngorhinootologie. 2003 Oct;82(10):700-6 [14593568.001]
  • [Cites] Laryngoscope. 2003 Nov;113(11):1922-6 [14603048.001]
  • [Cites] Laryngoscope. 2003 Dec;113(12):2174-81 [14660923.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2004 Apr;68(4):413-8 [15013606.001]
  • [Cites] Laryngoscope. 2004 Jul;114(7):1151-6 [15235339.001]
  • [Cites] Antiviral Res. 2004 Sep;63(3):141-51 [15451182.001]
  • [Cites] Thorax. 1985 Oct;40(10):797-8 [4060101.001]
  • [Cites] N Engl J Med. 1987 Oct 1;317(14):873-8 [2442608.001]
  • [Cites] Acta Otolaryngol. 1989 Jan-Feb;107(1-2):141-9 [2538994.001]
  • (PMID = 18458927.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  • [Number-of-references] 56
  • [Other-IDs] NLM/ PMC2441494
  •  go-up   go-down


5. Kumar B, Cordell KG, Lee JS, Prince ME, Tran HH, Wolf GT, Urba SG, Worden FP, Chepeha DB, Teknos TN, Eisbruch A, Tsien CI, Taylor JM, D'Silva NJ, Yang K, Kurnit DM, Bradford CR, Carey TE: Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender, and smoking. Int J Radiat Oncol Biol Phys; 2007;69(2 Suppl):S109-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender, and smoking.
  • Induction chemotherapy and concurrent chemoradiation for responders or immediate surgery for non-responders is an effective treatment strategy head and neck squamous cell carcinoma (HNSCC) of the larynx and oropharynx.
  • Biomarkers that predict outcome would be valuable in selecting patients for therapy.
  • In this study, the presence and titer of high risk human papilloma virus (HPV) and expression of epidermal growth factor receptor (EGFR) in pre-treatment biopsies, as well as smoking and gender were examined in oropharynx cancer patients enrolled in an organ sparing trial.
  • HPV16 copy number was positively associated with response to therapy and with overall and disease specific survival, whereas EGFR expression, current or former smoking behavior, and female gender (in this cohort) were associated with poor response and poor survival in multivariate analysis.
  • Smoking cessation and strategies to target EGFR may be useful adjuncts for therapy to improve outcome in the cases with the poorest biomarker profile.

  • MedlinePlus Health Information. consumer health - Smoking.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Otolaryngol Head Neck Surg. 1999 Nov;121(5):534-8 [10547465.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):709-20 [10793107.001]
  • [Cites] Head Neck. 2002 Sep;24(9):841-9 [12211048.001]
  • [Cites] Int J Cancer. 2003 Apr 10;104(3):336-44 [12569557.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2606-11 [16763272.001]
  • [Cites] Mol Cancer Ther. 2005 Jul;4(7):1096-104 [16020667.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5856-62 [16115926.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):593-8 [16380415.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):736-47 [16401683.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7683-8 [15914551.001]
  • (PMID = 17848274.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA046592-150011; United States / NIDCR NIH HHS / DE / R01 DE013346-05; United States / NCI NIH HHS / CA / P50 CA097248-05; United States / NCI NIH HHS / CA / CA097248-03S1; United States / NCI NIH HHS / CA / P50 CA97248; United States / NCI NIH HHS / CA / P50 CA097248-010002; United States / NCI NIH HHS / CA / P50 CA097248; United States / NIDCR NIH HHS / DE / DE013346-04; United States / NIDCR NIH HHS / DE / R01 DE013346; United States / NCI NIH HHS / CA / CA083087-04; United States / NIDCR NIH HHS / DE / DE013346-02; United States / NCI NIH HHS / CA / CA046592-150011; United States / NCI NIH HHS / CA / CA097248-04; United States / NCI NIH HHS / CA / R01 CA083087; United States / NCI NIH HHS / CA / R01 CA083087-01; United States / NCI NIH HHS / CA / P50 CA097248-04S1; United States / NIDCR NIH HHS / DE / R01 DE013346-01S1; United States / NCI NIH HHS / CA / P30 CA046592; United States / NCI NIH HHS / CA / R01 CA083087-05; United States / NCI NIH HHS / CA / P50 CA097248-01; United States / NCI NIH HHS / CA / P30 CA046592-140011; United States / NCI NIH HHS / CA / R01 CA083087-02; United States / NCI NIH HHS / CA / P30 CA46592; United States / NCI NIH HHS / CA / CA046592-140011; United States / NCI NIH HHS / CA / R01 CA83087; United States / NCI NIH HHS / CA / CA097248-04S1; United States / NIDCR NIH HHS / DE / DE013346-03; United States / NCI NIH HHS / CA / CA097248-010002; United States / NCI NIH HHS / CA / CA097248-01; United States / NIDCD NIH HHS / DC / P30 DC005188; United States / NCI NIH HHS / CA / CA083087-03; United States / NCI NIH HHS / CA / P50 CA097248-04; United States / NCI NIH HHS / CA / CA097248-05; United States / NIDCR NIH HHS / DE / R01 DE013346-03; United States / NCI NIH HHS / CA / P50 CA097248-03S1; United States / NCI NIH HHS / CA / R01 CA083087-03; United States / NIDCR NIH HHS / DE / R01 DE013346-02; United States / NCI NIH HHS / CA / P50 CA097248-02; United States / NIDCR NIH HHS / DE / DE013346-03S1; United States / NCI NIH HHS / CA / CA083087-02; United States / NCI NIH HHS / CA / CA083087-01; United States / NCI NIH HHS / CA / CA097248-02; United States / NIDCD NIH HHS / DC / P30 DC05188; United States / NIDCR NIH HHS / DE / DE013346-01S1; United States / NIDCR NIH HHS / DE / R01 DE013346-04; United States / NIDCR NIH HHS / DE / DE013346-01; United States / NCI NIH HHS / CA / R01 CA083087-04; United States / NIDCR NIH HHS / DE / DE013346-05; United States / NCI NIH HHS / CA / P50 CA097248-03; United States / NIDCR NIH HHS / DE / R01 DE13346; United States / NIDCR NIH HHS / DE / R01 DE013346-01; United States / NCI NIH HHS / CA / CA097248-03; United States / NCI NIH HHS / CA / CA083087-05; United States / NIDCR NIH HHS / DE / R01 DE013346-03S1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ NIHMS30942; NLM/ PMC2084353
  •  go-up   go-down


6. Cutts FT, Franceschi S, Goldie S, Castellsague X, de Sanjose S, Garnett G, Edmunds WJ, Claeys P, Goldenthal KL, Harper DM, Markowitz L: Human papillomavirus and HPV vaccines: a review. Bull World Health Organ; 2007 Sep;85(9):719-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Types 6 and 11 do not contribute to the incidence of high-grade dysplasias (precancerous lesions) or cervical cancer, but do cause laryngeal papillomas and most genital warts.
  • A quadrivalent (types 6, 11, 16 and 18) HPV vaccine has recently been licensed in several countries following the determination that it has an acceptable benefit/risk profile.
  • In large phase III trials, the vaccine prevented 100% of moderate and severe precancerous cervical lesions associated with types 16 or 18 among women with no previous infection with these types.
  • A bivalent (types 16 and 18) vaccine has also undergone extensive evaluation and been licensed in at least one country.
  • [MeSH-major] Papillomavirus Infections / drug therapy. Papillomavirus Vaccines / immunology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2004 Aug 20;111(2):278-85 [15197783.001]
  • [Cites] J Natl Cancer Inst. 2004 Apr 21;96(8):604-15 [15100338.001]
  • [Cites] J Virol. 1993 Jan;67(1):315-22 [8380079.001]
  • [Cites] Int J Gynecol Pathol. 1993 Apr;12(2):186-92 [8463044.001]
  • [Cites] Sex Transm Dis. 1995 Jul-Aug;22(4):236-43 [7482107.001]
  • [Cites] Sex Transm Dis. 1997 May;24(5):293-8 [9153740.001]
  • [Cites] Lancet. 2004 Nov 13-19;364(9447):1757-65 [15541448.001]
  • [Cites] J Infect Dis. 2004 Dec 15;190(12):2077-87 [15551205.001]
  • [Cites] Lancet Oncol. 2005 May;6(5):271-8 [15863374.001]
  • [Cites] J Infect Dis. 2005 Jun 1;191(11):1808-16 [15871112.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1157-64 [15894666.001]
  • [Cites] Pharmacoeconomics. 2005;23(11):1107-22 [16277547.001]
  • [Cites] Br J Cancer. 2005 Nov 28;93(11):1301-4 [16265348.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):326-33 [16492924.001]
  • [Cites] Lancet. 2006 Apr 15;367(9518):1247-55 [16631880.001]
  • [Cites] PLoS Med. 2006 May;3(5):e138 [16573364.001]
  • [Cites] Vaccine. 2006 Jul 7;24(27-28):5571-83 [16753240.001]
  • [Cites] N Engl J Med. 2006 Jun 22;354(25):2645-54 [16790697.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/171-7 [16844268.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/11-25 [16949997.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/132-9 [16950000.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/140-6 [16950001.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/178-86 [16950005.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/219-25 [16950010.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/227-32 [16950011.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/242-9 [16950013.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/26-34 [16950015.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/35-41 [16950016.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/42-51 [16950017.001]
  • [Cites] Int J Cancer. 2006 Dec 1;119(11):2677-84 [16991121.001]
  • [Cites] AIDS. 2006 Nov 28;20(18):2337-44 [17117020.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2148-53 [17119039.001]
  • [Cites] Int J Cancer. 2007 Aug 1;121(3):621-32 [17405118.001]
  • [Cites] Rev Panam Salud Publica. 1999 Oct;6(4):223-33 [10572472.001]
  • [Cites] J Infect Dis. 2000 Jun;181(6):1911-9 [10837170.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Feb;10(2):101-6 [11219765.001]
  • [Cites] N Engl J Med. 2002 Apr 11;346(15):1105-12 [11948269.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):63-73 [12556961.001]
  • [Cites] J Clin Microbiol. 2003 Jun;41(6):2509-14 [12791874.001]
  • [Cites] Br J Cancer. 2003 Jul 7;89(1):101-5 [12838308.001]
  • [Cites] Arch Pathol Lab Med. 2003 Aug;127(8):946-9 [12873166.001]
  • [Cites] Sex Transm Dis. 2003 Oct;30(10):788-93 [14520179.001]
  • [Cites] Virology. 1991 Nov;185(1):251-7 [1656586.001]
  • (PMID = 18026629.001).
  • [ISSN] 0042-9686
  • [Journal-full-title] Bulletin of the World Health Organization
  • [ISO-abbreviation] Bull. World Health Organ.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0100063
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  • [Number-of-references] 49
  • [Other-IDs] NLM/ PMC2636411
  •  go-up   go-down


7. Szyfter W, Wierzbicka M, Jackowska J, Bartochowska A, Banaszewski J: [The schedule of intralesional papillomatosis treatment with cidofovir]. Otolaryngol Pol; 2010 Mar-Apr;64(2):98-102
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The schedule of intralesional papillomatosis treatment with cidofovir].
  • It is characterized by proliferation of benign squamous cell papillomas within the respiratory-digestive tract, predominantly the larynx.
  • Standard treatment consists of surgical excision of papillomata to maintain airway patency and voice quality.
  • For last several years cidofovir is the most contemporary adjuvant anti-viral treatment for recurrent respiratory papillomatosis and its topical use is widely described.
  • MATERIAL AND METHODS: Intralesional cidofovir therapy was given to 20 patients treated for laryngeal papillomas in the Department of Otolaryngology in Poznan between I-XII.2009.
  • The number of cidofovir injections per patient varied from one to six times and the volume of solution ranges from 1-12 ml.
  • CONCLUSIONS: Intralesional cidofovir injection has been shown to be an effective an safe therapy for laryngeal papilloma and should be considered in those patients who experienced disease relapse.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Cytosine / analogs & derivatives. Laryngeal Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Organophosphonates / administration & dosage. Papilloma / drug therapy. Respiratory Tract Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Poland. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20568538.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


8. Wilson WR, Hashemiyoon R, Hawrych A: Intralesional cidofovir for recurrent laryngeal papillomas: preliminary report. Ear Nose Throat J; 2000 Apr;79(4):236-8, 240
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intralesional cidofovir for recurrent laryngeal papillomas: preliminary report.
  • This is a preliminary report of an ongoing study to test the efficacy of intralesional injections of the antiviral drug cidofovir in adults with recurrent laryngeal papillomas in whom multiple other treatments have previously failed.
  • Biopsies of the lesion sites were obtained at the initiation and completion of therapy.
  • No other treatment was given.
  • Resolution of lesions was monitored by videolaryngoscopy and still photography 1 to 2 weeks after each treatment.
  • In time, the lesions resolved in all three patients, although all three later experienced a minor recurrence.
  • We conclude that intralesional cidofovir appears to be a promising new treatment for controlling--and perhaps at higher dosages curing--refractory laryngeal papillomas, while causing little or no injury to laryngeal structures.
  • [MeSH-major] Antiviral Agents / administration & dosage. Cytosine / analogs & derivatives. Laryngeal Neoplasms / drug therapy. Organophosphonates. Organophosphorus Compounds / administration & dosage. Papilloma / drug therapy
  • [MeSH-minor] Adult. Clinical Protocols. Humans. Injections, Intralesional. Male. Middle Aged. Papillomaviridae / isolation & purification. Recurrence. Retreatment. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10786384.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Organophosphonates; 0 / Organophosphorus Compounds; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


9. Schraff S, Derkay CS, Burke B, Lawson L: American Society of Pediatric Otolaryngology members' experience with recurrent respiratory papillomatosis and the use of adjuvant therapy. Arch Otolaryngol Head Neck Surg; 2004 Sep;130(9):1039-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] American Society of Pediatric Otolaryngology members' experience with recurrent respiratory papillomatosis and the use of adjuvant therapy.
  • OBJECTIVE: To evaluate how evolving treatment technologies have affected our management of recurrent respiratory papilloma (RRP) since the last comprehensive survey of pediatric otolaryngologists in 1998.
  • A total of 150 (21%) of these patients presently receive adjuvant medical therapies with cidofovir and interferon, accounting for more than two thirds of the total.
  • Distal spread of RRP has occurred in 94 (13%) of the 700 patients.
  • The laryngeal microdebrider (53%) has supplanted the carbon dioxide laser (42%) as the preferred means of surgically removing papilloma from the larynx in children.
  • Routine human papillomavirus subtyping is practiced by 45% of respondents while 15% treat all their patients with antireflux medications.
  • CONCLUSIONS: Recurrent respiratory papilloma continues to be a frustrating disease to treat and is associated with significant morbidity and mortality.
  • There has been an evolution in the past decade toward the increased use of antiviral adjuvant therapy and the use of microdebrider techniques for surgical management.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antiviral Agents / therapeutic use. Cytosine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Organophosphonates. Papilloma / drug therapy. Respiratory Tract Neoplasms / drug therapy
  • [MeSH-minor] Australia. Chemotherapy, Adjuvant. Child. Child, Preschool. Debridement / methods. Europe. Health Care Surveys. Humans. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / surgery. Microsurgery. North America. Organophosphorus Compounds / therapeutic use

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIDOFOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15381589.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / Organophosphonates; 0 / Organophosphorus Compounds; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


10. Neumann K, Pudszuhn A, Welzel C, Bartel-Friedrich S, Passmann M: [Intralesional cidofovir injections for recurrent laryngeal papillomatosis: first results]. Laryngorhinootologie; 2003 Oct;82(10):700-6
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intralesional cidofovir injections for recurrent laryngeal papillomatosis: first results].
  • BACKGROUND: The treatment of recurrent laryngeal papillomatosis still presents an important therapeutic problem.
  • This primarily benign disease of the larynx is caused by an infection with the human papilloma virus (HPV) and forms epithelial neoplastic papillomas.
  • Therapy in larynx obstructing papillomatosis usually requires laser ablation.
  • Seven patients, age of five to 70 years, were treated with intralesional injections of Cidofovir after microlaryngoscopic ablation of laryngeal papillomas.
  • RESULTS AND CONCLUSIONS: After three to six sessions of laser ablation of the papillomas and intralesional injections with Cidofovir a distinct papilloma reduction could be observed in all patients and in two cases a complete remission was achieved.
  • The follow-up period of seven to 15 months revealed no recurrent laryngeal papillomatosis.
  • There were no local or systemic side-effects caused by the virustatic drug.
  • Intralesional injection of Cidofovir appears to develop into a promising adjuvant therapy option in recurrent laryngeal papillomatosis.
  • First results of the study seem to achieve a considerable reduction of the previously high rate of recurrence of laryngeal papillomatosis.
  • [MeSH-major] Antiviral Agents / administration & dosage. Cytosine / administration & dosage. Cytosine / analogs & derivatives. Laryngeal Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Organophosphonates. Organophosphorus Compounds / administration & dosage. Papilloma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Airway Obstruction / drug therapy. Airway Obstruction / pathology. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Drug Administration Schedule. Female. Humans. Inclusion Bodies, Viral / drug effects. Inclusion Bodies, Viral / ultrastructure. Injections, Intralesional. Larynx / drug effects. Larynx / pathology. Larynx / surgery. Laser Therapy. Male. Microscopy, Electron. Middle Aged. Pilot Projects. Prospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Laryngeal papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14593568.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Organophosphonates; 0 / Organophosphorus Compounds; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


11. Xiao P, Zhang XS: Adult laryngotracheal surgery. Anesthesiol Clin; 2010 Sep;28(3):529-40
MedlinePlus Health Information. consumer health - Anesthesia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The human larynx plays a pivotal role in airway protection, respiration, and phonation.
  • Laryngeal disorders can be divided into two categories, benign lesions and malignant lesions.
  • Most benign lesions are treatable with surgery and speech therapy, whereas the malignant lesions require more invasive surgery as well as radiation and chemotherapy.
  • [MeSH-major] Anesthesia. Larynx / surgery. Trachea / surgery
  • [MeSH-minor] Adult. Anesthesia, General. Humans. Laryngeal Diseases / surgery. Laryngeal Neoplasms / diagnosis. Laryngeal Neoplasms / epidemiology. Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / surgery. Laryngectomy. Papilloma / surgery. Preoperative Care. Reconstructive Surgical Procedures. Tracheitis / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20850083.001).
  • [ISSN] 1932-2275
  • [Journal-full-title] Anesthesiology clinics
  • [ISO-abbreviation] Anesthesiol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


12. Pudszuhn A, Welzel C, Bloching M, Neumann K: Intralesional Cidofovir application in recurrent laryngeal papillomatosis. Eur Arch Otorhinolaryngol; 2007 Jan;264(1):63-70
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intralesional Cidofovir application in recurrent laryngeal papillomatosis.
  • Recurrent laryngeal papillomatosis is a benign disease of the larynx often leading to organic and functional restrictions.
  • The therapeutic treatment of choice in larynx-obstructing papillomatosis is at present surgical laser ablation.
  • The effectiveness of adjuvant intralesional injection of the virustaticum Cidofovir has been investigated recently in a variety of therapeutic models.
  • The present case study deals with the treatment of recurrent laryngeal papillomatosis by means of surgical laser ablation of the laryngeal papillomas with adjuvant local injection of the virustaticum Cidofovir (dose of 5 mg/1 ml).
  • Papillomatosis was confirmed histologically in all cases, and the virus types were defined in part.
  • After 2-7 treatments with surgical laser papilloma ablation and intralesional Cidofovir injections, all patients showed a definite papilloma reduction, while in six cases complete remission was achieved.
  • During the follow-up period of 8-30 months, not a single recurrence of the laryngeal papillomatosis occurred.
  • Intralesional injection of Cidofovir is an adjuvant, but not a curative therapeutic option in recurrent laryngeal papillomatosis.
  • Remission of previously frequently recurrent laryngeal papillomas can be achieved, but recurrence after longer treatment-free intervals is also possible.
  • [MeSH-major] Antiviral Agents / therapeutic use. Cytosine / analogs & derivatives. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / pathology. Organophosphonates / therapeutic use. Papilloma / drug therapy. Papilloma / pathology
  • [MeSH-minor] Adult. Aged. Child, Preschool. Combined Modality Therapy. Female. Human papillomavirus 11 / isolation & purification. Human papillomavirus 6 / isolation & purification. Humans. Laryngeal Mucosa / pathology. Laryngeal Mucosa / virology. Laser Therapy. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Remission Induction

  • Genetic Alliance. consumer health - Laryngeal papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Otol Rhinol Laryngol. 2003 Apr;112(4):298-302 [12731623.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Aug;129(8):841-6 [12925342.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2002 Nov;259(10):516-20 [12434183.001]
  • [Cites] J Med Virol. 1998 Mar;54(3):219-25 [9515772.001]
  • [Cites] Laryngoscope. 2003 Sep;113(9):1583-7 [12972938.001]
  • [Cites] Ear Nose Throat J. 2000 Apr;79(4):236-8, 240 [10786384.001]
  • [Cites] Drugs. 1996 Aug;52(2):225-230; discussion 231 [8841740.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1999 Oct;125(10):1143-8 [10522508.001]
  • [Cites] Laryngoscope. 2003 Dec;113(12):2174-81 [14660923.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1999 Jul;125(7):743-8 [10406310.001]
  • [Cites] Otolaryngol Head Neck Surg. 1999 May;120(5):698-705 [10229596.001]
  • [Cites] J Med Virol. 1995 Feb;45(2):230-5 [7775945.001]
  • [Cites] Verh K Acad Geneeskd Belg. 2001;63(2):93-120, discussion 120-2 [11436421.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2003 Dec;11(6):433-41 [14631175.001]
  • [Cites] Laryngoscope. 2001 Jan;111(1):57-69 [11192901.001]
  • [Cites] Otolaryngol Clin North Am. 2000 Oct;33(5):1127-42 [10984775.001]
  • [Cites] Arch Pathol Lab Med. 2002 Oct;126(10):1184-8 [12296755.001]
  • [Cites] Semin Cancer Biol. 1999 Dec;9(6):379-86 [10712884.001]
  • [Cites] Otolaryngol Head Neck Surg. 1995 Feb;112(2):197-202 [7530830.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1999;256(9):450-4 [10552224.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2000 Oct;126(10):1239-43 [11031411.001]
  • [Cites] Laryngoscope. 2004 Jul;114(7):1151-6 [15235339.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2004 Apr;68(4):413-8 [15013606.001]
  • [Cites] Chest. 2000 Oct;118(4):1210-4 [11035700.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Oct;129(10):1081-5 [14568791.001]
  • [Cites] Pediatr Infect Dis J. 1998 May;17(5):372-6 [9613648.001]
  • [Cites] Laryngorhinootologie. 2003 Oct;82(10):700-6 [14593568.001]
  • [Cites] Laryngoscope. 1998 Jun;108(6):935-7 [9628513.001]
  • [Cites] Laryngoscope. 2002 Apr;112(4):696-9 [12150526.001]
  • (PMID = 17058091.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


13. Bielamowicz S, Villagomez V, Stager SV, Wilson WR: Intralesional cidofovir therapy for laryngeal papilloma in an adult cohort. Laryngoscope; 2002 Apr;112(4):696-9
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intralesional cidofovir therapy for laryngeal papilloma in an adult cohort.
  • OBJECTIVES: To confirm the safety and efficacy of intralesional cidofovir in the management of laryngeal papilloma and to identify variables that correlate with number of injections needed to achieve remission.
  • STUDY DESIGN: An open-trial prospective evaluation of the efficacy of intralesional cidofovir in subjects with laryngeal papilloma.
  • METHODS: Fourteen adult subjects with biopsy-proven laryngeal papilloma were enrolled in a treatment study of intralesional cidofovir.
  • Injections were repeated until no papilloma could be visually identified during an intraoperative evaluation.
  • RESULTS: All subjects have achieved disease remission using an injection-only treatment protocol.
  • No additional laryngeal scarring or systemic toxicity was identified.
  • CONCLUSIONS: Intralesional injection of cidofovir is an excellent treatment option with limited local and systemic toxicities.
  • The injection therapy regimen requires perseverance from both patient and surgeon.
  • Remission of disease can be achieved in adults with laryngeal papilloma.
  • [MeSH-major] Antiviral Agents / administration & dosage. Cytosine / administration & dosage. Laryngeal Neoplasms / drug therapy. Organophosphonates. Organophosphorus Compounds / administration & dosage. Papilloma / drug therapy
  • [MeSH-minor] Cohort Studies. Drug Administration Schedule. Female. Humans. Injections, Intralesional. Male. Middle Aged

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12150526.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Organophosphonates; 0 / Organophosphorus Compounds; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


14. Szydłowski J, Cofta J, Wiktorowicz K, Grzegorowski M: [The interaction of stilbazolium merocyanines with hyperproliferative laryngeal papilloma cells--preliminary study]. Otolaryngol Pol; 2003;57(6):823-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The interaction of stilbazolium merocyanines with hyperproliferative laryngeal papilloma cells--preliminary study].
  • Recently increasing interest focused in possible clinical application on photodynamic therapy was observed.
  • Many scientists are looking for new chemical compounds effective in therapy and giving no side effects.
  • The aim of this study was to estimate the usefulness of the selected stilbazolium merocyanines to treatment on human recurrent respiratory papillomatosis.
  • Tissue samples were analyzed for presence of Human papillomavirus (HPV).
  • The incorporation of the dye into papillomas cells membranes was measured by flow cytometry.
  • The hyperplastic tissue showed the highest fluorescence intensity than normal epithelium.
  • [MeSH-major] Benzylidene Compounds / pharmacology. Dihydropyridines / pharmacology. Laryngeal Neoplasms / drug therapy. Papilloma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15049182.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Benzylidene Compounds; 0 / Dihydropyridines; 0 / stilbazolium merocyanine
  •  go-up   go-down


15. Bielecki I, Mniszek J, Cofała M: Intralesional injection of cidofovir for recurrent respiratory papillomatosis in children. Int J Pediatr Otorhinolaryngol; 2009 May;73(5):681-4
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Papillomatosis of the larynx appears as the result of an infection by the human papilloma virus (HPV).
  • There is currently no effective therapy for recurrent respiratory papillomatosis (RRP).
  • The basic goal of treatment is to preserve the patency of air passages while simultaneously preserving the phonatory and anatomical functioning of the larynx.
  • Over the last 10 years, the possibility of a pharmacological treatment has been continually explored: in particular, the administration of locally passed cidofovir (first reported in a 1999 study by Pransky) to the larynx with papillomas is under current scrutiny.
  • GOAL OF STUDY: The goal of the following study is to estimate the effectiveness of locally administered cidofovir for treatment of papillomas of the larynx in children.
  • RESULTS: Seven of the 10 patients achieved total remission 6 months after the completion of treatment, scoring 0 points on Derkay's scale.
  • These patients underwent therapy with cidofovir from 6 to 13 months.
  • Three months after the completion of treatment, three children suffered a recurrence of papillomas.
  • CONCLUSIONS: The results of the study indicate that intralesional injections of cidofovir can be an effective method of treatment for recurrent respiratory papillomatosis in children.
  • [MeSH-major] Antiviral Agents / therapeutic use. Cytosine / analogs & derivatives. Laryngeal Neoplasms / drug therapy. Organophosphonates / therapeutic use. Papilloma / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Injections, Intramuscular. Laryngeal Muscles. Male. Neoplasm Recurrence, Local. Neoplasm Staging. Remission Induction

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19193450.001).
  • [ISSN] 1872-8464
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


16. Lesinski-Schiedat A, Hemmanouil I, Sauer-Gönen M, Flemming P, Freihorst I, Kempf HG, Lenarz T: [Malignant transformation of a juvenile papilloma in a 11 year old boy]. Laryngorhinootologie; 2005 Aug;84(8):602-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant transformation of a juvenile papilloma in a 11 year old boy].
  • BACKGROUND: The juvenile laryngeal papilloma is the most common benign neoplasm in children.
  • Sporadic malignant transformation in adults with a papilloma was reported after treatment with radiotherapy alone or in combination with the intake of additional toxins (e. g. nicotine).
  • Similar reports of a malignant transformation of juvenile papillomas without additional risk factors is very rarely reported.
  • CASE REPORT: We report about an 11 year old boy, who suffered from a juvenile laryngeal papilloma.
  • The multiple laser surgical procedures and a therapy with interferon resulted in a short-term remissions.
  • Seven months after the first diagnosis of the papilloma a regional metastatic squamous cell carcinoma was found.
  • In spite of combined radiotherapy and chemotherapy the boy died 11 months later.
  • CONCLUSIONS: The spontaneous malignant transformation of a juvenile papilloma in a squamous cell carcinoma is extremely rare.
  • The surgical intervention as well the radiotherapy and chemotherapy using interferon was unsuccessful due to the high grade of malignancy.
  • In view of the very short time interval between first diagnosis of juvenile papilloma and the subsequent malignant transformation, one must consider either the potential presence of a very aggressive form of papilloma or alternative two coincident independent diseases.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Cell Transformation, Neoplastic / pathology. Laryngeal Neoplasms / pathology. Papilloma / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child. Humans. Interferons / therapeutic use. Magnetic Resonance Imaging. Male. Remission Induction. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080063.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 9008-11-1 / Interferons
  •  go-up   go-down


17. Tanna N, Sidell D, Joshi AS, Bielamowicz SA: Adult intralesional cidofovir therapy for laryngeal papilloma: a 10-year perspective. Arch Otolaryngol Head Neck Surg; 2008 May;134(5):497-500
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult intralesional cidofovir therapy for laryngeal papilloma: a 10-year perspective.
  • OBJECTIVE: To assess the long-term efficacy of intralesional cidofovir therapy in a previously reported cohort of adult subjects with laryngeal papilloma.
  • PATIENTS: We previously reported on the favorable clinical response to intralesional cidofovir therapy in 13 adult subjects.
  • The subjects were enrolled in an open-trial prospective study (1997-2001) and completed the injection-only treatment protocol, and all subjects achieved a disease remission after a mean of 6 injections.
  • The remaining 7 patients (54%) required further treatment for disease relapse, with a mean duration of remission before relapse of 1.05 years.
  • Of the 7 patients who experienced disease relapse, 2 continued to have stable disease with regular injections, 2 were lost to follow-up during relapse treatment, and 3 achieved disease remission again.
  • CONCLUSION: Intralesional cidofovir injections have been shown to be an effective therapy for adult laryngeal papilloma and should be considered in those patients who experience disease relapse.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Cytosine / analogs & derivatives. Laryngeal Neoplasms / drug therapy. Organophosphonates / administration & dosage. Papilloma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Injections, Intralesional. Male. Middle Aged. Recurrence. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18490570.001).
  • [ISSN] 1538-361X
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


18. Lott DG, Krakovitz PR: Squamous cell carcinoma associated with intralesional injection of cidofovir for recurrent respiratory papillomatosis. Laryngoscope; 2009 Mar;119(3):567-70
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma associated with intralesional injection of cidofovir for recurrent respiratory papillomatosis.
  • Recurrent respiratory papillomatosis is a common neoplasm of the larynx that may lead to severe, recurrent lesions.
  • Intralesional injection of cidofovir has shown promise as an adjuvant therapy.
  • We report a case of invasive squamous cell cancer arising from squamous papilloma in a patient treated with multiple injections of cidofovir.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Carcinoma, Squamous Cell / chemically induced. Cytosine / analogs & derivatives. Neoplasms, Second Primary / chemically induced. Organophosphonates / adverse effects. Papilloma / drug therapy. Tracheal Neoplasms / drug therapy
  • [MeSH-minor] Child. Female. Follow-Up Studies. Humans. Injections, Intralesional / adverse effects. Otorhinolaryngologic Surgical Procedures / methods. Tomography, X-Ray Computed. Trachea / surgery

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Laryngoscope. 2010 Mar;120(3):650; author reply 651 [20013845.001]
  • (PMID = 19235765.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


19. Wemer RD, Lee JH, Hoffman HT, Robinson RA, Smith RJ: Case of progressive dysplasia concomitant with intralesional cidofovir administration for recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol; 2005 Nov;114(11):836-9
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recurrent respiratory papillomatosis (RRP) is characterized by benign wartlike growths in the larynx with occasional spread to the lungs.
  • A broad range of therapeutic measures have been used to treat RRP; the primary treatment is laser vaporization of the lesions.
  • Recurrences of the disease are common, and alternate methods of treatment are being used to prevent recurrence, including cidofovir.
  • Cidofovir is a cytosine nucleotide analog with antiviral properties that is approved by the US Food and Drug Administration for treatment of cytomegalovirus retinitis and is currently being used off-label for RRP.
  • Cidofovir has gained initial success in slowing the rate of disease recurrence when used at the time of surgery.
  • We report here a 28-year-old woman who was treated with intralesional cidofovir at the time of surgery over the span of 27 months.
  • The initial pathology results demonstrated benign disease with progression to severe dysplasia during the treatment time.
  • [MeSH-major] Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / pathology. Papilloma / drug therapy. Papilloma / pathology

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Otol Rhinol Laryngol. 2005 Nov;114(11):834-5 [16358602.001]
  • (PMID = 16358603.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


20. Okubo K, Saito K, Fukuda H, Watanabe K, Ogawa K, Shiotani A: Traditional Chinese Medicine for treatment of laryngeal papillomatosis. J Altern Complement Med; 2010 Apr;16(4):427-33
MedlinePlus Health Information. consumer health - Herbal Medicine.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Traditional Chinese Medicine for treatment of laryngeal papillomatosis.
  • OBJECTIVE: The objective of this study was to assess the clinical effectiveness of Traditional Chinese Medicine (TCM) as an adjuvant therapy for recurrent respiratory papillomatosis.
  • LOCATION AND SUBJECTS: Fifty-one (51) patients with laryngeal papillomatosis who were treated at Keio University Hospital between May 1981 and April 2008 were incorporated in this study.
  • INTERVENTIONS: Individually formulated TCM was orally administered postsurgically to 20 patients with aggressive laryngeal papillomatosis requiring multiple laser ablations (at least biannually) because of frequent recurrence.
  • Eight (8) patients were excluded because of discontinued visits or medication (6 patients), or malignant transformation of the lesion (2 patients).
  • OUTCOME MEASURES: Retrospective chart review and review of the patients' recorded laryngeal images were performed.
  • CONCLUSIONS: TCM may be a useful adjuvant therapy to treat aggressive laryngeal papillomatosis.
  • Further studies are necessary to clarify the pharmacological mechanism of TCM in the treatment of laryngeal papillomatosis.
  • [MeSH-major] Drugs, Chinese Herbal / therapeutic use. Laryngeal Neoplasms / drug therapy. Larynx / drug effects. Outcome Assessment (Health Care). Papilloma / drug therapy. Phytotherapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Child. Female. Humans. Infant. Male. Medicine, Chinese Traditional. Retrospective Studies. Severity of Illness Index

  • Genetic Alliance. consumer health - Laryngeal papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20423212.001).
  • [ISSN] 1557-7708
  • [Journal-full-title] Journal of alternative and complementary medicine (New York, N.Y.)
  • [ISO-abbreviation] J Altern Complement Med
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal
  •  go-up   go-down


21. Nowaczewska K, Wójtowicz P, Kukwa A, Ratajczak J, Tulibacki M: [Respiratory papillomatosis--new methods of treatment]. Otolaryngol Pol; 2010 Jan-Feb;64(1):31-6
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Respiratory papillomatosis--new methods of treatment].
  • The most common location in head and neck is larynx, palatine tonsils and arches of palate, uvula and mucosa oral and nasal cavity.
  • The aim of this study was to estimate new methods of treatment respiratory papillomatosis based on intralesional injection of cidofovir into sites where papillomas had just been excised.
  • The treatment was based on surgical excision of papilloma and after it intralesional injection of cidofovir in after 4-5 weeks.
  • 41 patients had 4 times intralesional injection of cidofovir.
  • 18 patients had increased number of injection of ciodofovir because of recurrent papilloma.
  • CONCLUSION: Surgery with intralesional cidofovir injection in the place after removal of papilloma is very effective methods.
  • We observed that this treatment caused long lasting remission of papilloma recurrence.
  • [MeSH-major] Antiviral Agents / administration & dosage. Cytosine / analogs & derivatives. Laryngeal Neoplasms / drug therapy. Organophosphonates / administration & dosage. Papilloma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Drug Administration Schedule. Female. Humans. Injections, Intralesional. Male. Middle Aged. Neoplasm Staging. Poland. Remission Induction. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20476590.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


22. Lin HW, Richmon JD, Emerick KS, de Venecia RK, Zeitels SM, Faquin WC, Lin DT: Malignant transformation of a highly aggressive human papillomavirus type 11-associated recurrent respiratory papillomatosis. Am J Otolaryngol; 2010 Jul-Aug;31(4):291-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of a highly aggressive human papillomavirus type 11-associated recurrent respiratory papillomatosis.
  • OBJECTIVE: The objective is to present an uncommon case of squamous cell carcinoma (SCC) arising from extensive recurrent respiratory papillomatosis (RRP) involving the upper and lower airway and temporal bone.
  • METHODS: We describe a case of a 24-year-old woman with a history of human papillomavirus (HPV) type 11 since childhood originating in the larynx and trachea, then progressing to involve the distal pulmonary alveoli and right middle ear through the eustachian tube.
  • Papillomatous growth was treated with multiple surgeries including laser cytoreduction of laryngotracheal papillomatosis and radical mastoidectomy, followed by a trial of chemotherapy.
  • Despite this aggressive treatment regimen, papillomatous growth progressed with recurrence in the right eustachian tube, middle ear, and mastoid eventually extending to involve the calvaria and scalp.
  • RESULTS: The patient underwent a composite resection of involved tissues, including the scalp, auricle, and lateral temporal bone, with reconstruction using a latissimus dorsi free flap.
  • Final pathologic analysis revealed an extensive infiltrative well-differentiated SCC arising from the papilloma.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Human papillomavirus 11. Papilloma / pathology. Respiratory Tract Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Disease Progression. Female. Humans. Neoplasm Recurrence, Local. Tomography, X-Ray Computed. Young Adult

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20015762.001).
  • [ISSN] 1532-818X
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Dancey DR, Chamberlain DW, Krajden M, Palefsky J, Alberti PW, Downey GP: Successful treatment of juvenile laryngeal papillomatosis-related multicystic lung disease with cidofovir: case report and review of the literature. Chest; 2000 Oct;118(4):1210-4
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of juvenile laryngeal papillomatosis-related multicystic lung disease with cidofovir: case report and review of the literature.
  • Cidofovir, a nucleoside analog antiviral agent, has been used with moderate success in the treatment of juvenile laryngeal papillomatosis (JLP) by direct intralesional injection.
  • A 35-year-old woman with a history of JLP requiring multiple laser ablations of laryngeal papillomata each year presented with hemoptysis and was found on CT scan to have bilateral, multiple pulmonary nodules and cysts.
  • Molecular DNA typing of a biopsy specimen obtained from a laryngeal papilloma confirmed infection with human papilloma virus type 11.
  • She received 12 months of treatment with IV cidofovir followed by 9 months of combined treatmentwith IV cidofovir and subcutaneous interferon-alpha-2A.
  • This therapeutic regime resulted in a markedly decreased requirement for surgical removal of laryngeal papillomata, and CT scanning documented the regression of the lesions in the lung parenchyma that persisted after the discontinuation of therapy.
  • [MeSH-major] Antiviral Agents / therapeutic use. Cystic Adenomatoid Malformation of Lung, Congenital / complications. Cytosine / analogs & derivatives. Cytosine / therapeutic use. Laryngeal Neoplasms / drug therapy. Organophosphonates. Organophosphorus Compounds / therapeutic use. Papilloma / drug therapy
  • [MeSH-minor] Adult. Biopsy. DNA, Viral / analysis. Diagnosis, Differential. Female. Humans. Papillomaviridae / genetics. Papillomaviridae / isolation & purification. Papillomavirus Infections / complications. Papillomavirus Infections / diagnosis. Papillomavirus Infections / drug therapy. Papillomavirus Infections / virology. Tomography, X-Ray Computed. Tumor Virus Infections / complications. Tumor Virus Infections / diagnosis. Tumor Virus Infections / drug therapy. Tumor Virus Infections / virology

  • Genetic Alliance. consumer health - Laryngeal papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11035700.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / DNA, Viral; 0 / Organophosphonates; 0 / Organophosphorus Compounds; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  • [Number-of-references] 35
  •  go-up   go-down


24. Van Valckenborgh I, Wellens W, De Boeck K, Snoeck R, De Clercq E, Feenstra L: Systemic cidofovir in papillomatosis. Clin Infect Dis; 2001 Feb 1;32(3):E62-4
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An 8-year-old patient with severe recurrent respiratory papillomatosis and pulmonary spread was treated by systemic administration of cidofovir in association with laser treatment for tracheal lesions.
  • Complete disappearance of the lesions in the pharynx and larynx and a significant yet incomplete regression in the bronchi and lung parenchyma were observed without deleterious side effects.
  • [MeSH-major] Antiviral Agents / therapeutic use. Cytosine / analogs & derivatives. Cytosine / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Organophosphonates. Organophosphorus Compounds / therapeutic use. Papilloma / drug therapy. Respiratory Tract Neoplasms / drug therapy
  • [MeSH-minor] Child. Female. Humans. Neoplasm Invasiveness. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11170974.001).
  • [ISSN] 1058-4838
  • [Journal-full-title] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • [ISO-abbreviation] Clin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Organophosphonates; 0 / Organophosphorus Compounds; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


25. Getz AE, Scharf J, Amin MR: Thyrohyoid approach to cidofovir injection: a case study. J Voice; 2005 Sep;19(3):501-3
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Various techniques for injection into the larynx have been well described, including transoral injection with indirect laryngoscopy or direct laryngoscopy and transcutaneous injection through the thyroid cartilage or cricothyroid membrane.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Cytosine / analogs & derivatives. Laryngeal Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Organophosphonates / administration & dosage. Papilloma / drug therapy
  • [MeSH-minor] Humans. Injections, Intralesional / methods. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16102676.001).
  • [ISSN] 0892-1997
  • [Journal-full-title] Journal of voice : official journal of the Voice Foundation
  • [ISO-abbreviation] J Voice
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


26. Shikowitz MJ, Abramson AL, Steinberg BM, DeVoti J, Bonagura VR, Mullooly V, Nouri M, Ronn AM, Inglis A, McClay J, Freeman K: Clinical trial of photodynamic therapy with meso-tetra (hydroxyphenyl) chlorin for respiratory papillomatosis. Arch Otolaryngol Head Neck Surg; 2005 Feb;131(2):99-105
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical trial of photodynamic therapy with meso-tetra (hydroxyphenyl) chlorin for respiratory papillomatosis.
  • OBJECTIVE: To determine the efficacy of photodynamic therapy (PDT) with meso-tetra (hydroxyphenyl) chlorin (m-THPC) photosensitizer for recurrent respiratory papillomatosis.
  • DESIGN: Parallel-arm, randomized trial of patients requiring surgery at least 3 times yearly with single PDT 6 or 18 months after enrollment and 12-month follow-up.
  • Disease extent was scored and papillomas were removed during direct endoscopy every 3 months after enrollment.
  • RESULTS: There were significant differences between groups, with marked improvement in laryngeal disease across time after PDT (P = .006).
  • Five of 15 patients were in remission 12 to 15 months after treatment, but there was recurrence of disease after 3 to 5 years.
  • CONCLUSIONS: Use of m-THPC PDT reduces the severity of laryngeal papillomas, possibly through an improved immune response.
  • Failure to maintain remission with time suggests that this is not an optimal treatment.
  • [MeSH-major] Laryngeal Neoplasms / drug therapy. Mesoporphyrins / therapeutic use. Papilloma / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Remission Induction. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15723939.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Grant] United States / NIDCD NIH HHS / DC / P50 DC00203
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mesoporphyrins; 0 / Photosensitizing Agents; FU21S769PF / temoporfin
  •  go-up   go-down


27. Elackattu AP, Feng L, Wang Z: A controlled safety study of diindolylmethane in the immature rat model. Laryngoscope; 2009 Sep;119(9):1803-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES/HYPOTHESIS: Diindolylmethane (DIM), a natural product from cruciferous vegetables, has been shown to be a dietary component that has inhibitory effects on some tumors (e.g., laryngeal papilloma).
  • METHODS: Forty rats were separated into four treatment groups of 10 rats each, based on the amount of study drug they received in their daily food:.
  • CONCLUSIONS: Diindolylmethane seems to have no adverse affects on the rat even when given in doses 3x what we propose to be therapeutic.
  • This adds evidence to the safety of this drug in the pediatric population as a treatment option for recurrent respiratory papilloma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cancer Ther. 2002 Nov;1(13):1161-72 [12479697.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2009 May;73(5):681-4 [19193450.001]
  • [Cites] J Voice. 2004 Jun;18(2):248-53 [15193659.001]
  • [Cites] J Toxicol Environ Health. 1987;21(3):311-23 [3495667.001]
  • [Cites] Anticancer Res. 1993 Mar-Apr;13(2):337-41 [8390800.001]
  • [Cites] Anticancer Res. 1998 Nov-Dec;18(6B):4569-73 [9891520.001]
  • [Cites] J Med Virol. 2005 Feb;75(2):332-5 [15602729.001]
  • [Cites] Mol Pharmacol. 2006 Apr;69(4):1320-7 [16385077.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4880-7 [16651444.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2006 Sep;115(9):679-85 [17044539.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6502-11 [17616712.001]
  • [Cites] Otolaryngol Head Neck Surg. 2007 Sep;137(3):477-81 [17765779.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 2008 Mar 11;88(10):661-4 [18642764.001]
  • [Cites] In Vivo. 2008 Jul-Aug;22(4):441-5 [18712169.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2619-24 [18843002.001]
  • [Cites] J Nutr. 2009 Jan;139(1):26-32 [19056653.001]
  • [Cites] J Cell Physiol. 2009 Apr;219(1):94-9 [19062173.001]
  • [Cites] Toxicol Sci. 2003 Jul;74(1):10-21 [12730619.001]
  • (PMID = 19544380.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] ENG
  • [Grant] United States / NIDCD NIH HHS / DC / DC008287-02; United States / NIDCD NIH HHS / DC / R01 DC008287; United States / NIDCD NIH HHS / DC / 5R01DC008287-02; United States / NIDCD NIH HHS / DC / R01 DC008287-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indoles; 0 / diindolylmethane; 1406-16-2 / Vitamin D
  • [Other-IDs] NLM/ NIHMS115765; NLM/ PMC3015182
  •  go-up   go-down


28. Karimova FS, Ivanchenko GF, Grigorian SS: [The treatment of laryngeal papillomatosis with interferon inducers]. Vestn Otorinolaringol; 2000;(5):54-7
Genetic Alliance. consumer health - Laryngeal papillomatosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The treatment of laryngeal papillomatosis with interferon inducers].
  • Seventy three patients aged 16 to 88 years who had laryngeal papillomatosis (LP) were followed up.
  • Microsurgical endolaryngeal removal of laryngeal papillomas was made in all the patients.
  • The interferon inducers amixine and cycloferon as antirecurrent drugs were used in 45 patients by the regime the authors developed by taking into account the interferon status and cellular immunity of patients.
  • The criteria for the efficiency of treatment were their improved interferon status and longer remission.
  • The efficiency of treatment with amixine and cycloferon was 72 and 80%, respectively.
  • Thus, the use of a sparing microsurgical intervention in combination with interferon inducers may be regarded as the method of choice in the LP treatment.
  • [MeSH-major] Acridines / therapeutic use. Interferon Inducers / therapeutic use. Laryngeal Neoplasms / drug therapy. Papilloma / drug therapy. Tilorone / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Microsurgery. Middle Aged. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11051860.001).
  • [ISSN] 0042-4668
  • [Journal-full-title] Vestnik otorinolaringologii
  • [ISO-abbreviation] Vestn. Otorinolaringol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] RUSSIA
  • [Chemical-registry-number] 0 / Acridines; 0 / Interferon Inducers; 38609-97-1 / 10-carboxymethyl-9-acridanone; O6W7VEW6KS / Tilorone
  •  go-up   go-down


29. Armbruster C, Kreuzer A, Vorbach H, Huber M, Armbruster C: Successful treatment of severe respiratory papillomatosis with intravenous cidofovir and interferon alpha-2b. Eur Respir J; 2001 Apr;17(4):830-1
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of severe respiratory papillomatosis with intravenous cidofovir and interferon alpha-2b.
  • In contrast to uncomplicated juvenile laryngeal papillomas which may regress spontaneously, papillomatosis involving pulmonary parenchyma is associated with a poor outcome.
  • Bronchoscopy revealed polypoid lesions of the right vocal cord and the midtrachea which were confirmed as squamous papillomatosis by histology.
  • Interferon (IFN)alpha-2b treatment was inefficient as was cidofovir monotherapy on a maintenance basis.
  • Six months of IFN-alpha-2b and cidofovir in combination led to a complete macroscopic disappearance of the laryngeal lesions and to an impressive regression of the tracheal papillomas and of the intrapulmonary consolidations.
  • Probably the same mechanisms as in ribavirin plus interferon alpha-2b, in the treatment of patients with chronic hepatitis C, are responsible for the therapeutic success in this case.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cytosine / administration & dosage. Cytosine / analogs & derivatives. Interferon-alpha / administration & dosage. Lung Neoplasms / drug therapy. Organophosphonates. Organophosphorus Compounds / administration & dosage. Papilloma / drug therapy. Tracheal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Female. Humans. Injections, Intravenous. Laryngeal Neoplasms / drug therapy. Recombinant Proteins

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11401080.001).
  • [ISSN] 0903-1936
  • [Journal-full-title] The European respiratory journal
  • [ISO-abbreviation] Eur. Respir. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Organophosphonates; 0 / Organophosphorus Compounds; 0 / Recombinant Proteins; 8J337D1HZY / Cytosine; 99210-65-8 / interferon alfa-2b; JIL713Q00N / cidofovir
  •  go-up   go-down


30. Lindsay F, Bloom D, Pransky S, Stabley R, Shick P: Histologic review of cidofovir-treated recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol; 2008 Feb;117(2):113-7
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Recurrent respiratory papillomatosis is currently the most common lesion of the larynx in children.
  • Cidofovir is an antiviral drug with activity against members of the DNA virus family.
  • CONCLUSIONS: This is the first report of pathologically evaluated recurrent respiratory papillomatosis specimens taken before and after treatment with intralesional cidofovir.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cytosine / analogs & derivatives. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Organophosphonates / therapeutic use. Papilloma / drug therapy. Papilloma / pathology

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18357834.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


31. Tsvetkov EA, Sel'kov SA, Chmyreva NN: [Interferon therapy and immunotherapy in children with respiratory papillomatosis]. Vestn Otorinolaringol; 2002;(2):34-6
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Interferon therapy and immunotherapy in children with respiratory papillomatosis].
  • 111 of them had laryngeal papillomatosis.
  • The scheme of combined treatment was adjusted to interferon status of the patients.
  • Replacement therapy with recombinant interferon--viferon--was applied in low production of alpha/beta-interferon but high serum interferon.
  • In low serum interferon and intact interferon reserves the treatment was combined: interferon inductor--cycloferon plus viferon.
  • In all the children the above treatment was given following surgical (microendoscopic) removal of laryngeal papillomas.
  • The clinical course of laryngeal papillomatosis ran in accordance with changes of interferon status in the majority of cases.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Antineoplastic Agents / therapeutic use. Interferon-beta / therapeutic use. Interferon-gamma / therapeutic use. Papilloma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12056158.001).
  • [ISSN] 0042-4668
  • [Journal-full-title] Vestnik otorinolaringologii
  • [ISO-abbreviation] Vestn. Otorinolaringol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antineoplastic Agents; 77238-31-4 / Interferon-beta; 82115-62-6 / Interferon-gamma
  •  go-up   go-down






Advertisement